Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma.

(2017) M. Ellegaard et al.   JOURNAL OF CLINICAL ONCOLOGY

Toll-like receptors as targets for immune disorders

(2011) Brian Keogh et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

(2009) Brenda K. Edwards et al.   CANCER

International Trends in Colorectal Cancer Incidence Rates

(2009) M. M. Center et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

(2009) Davide Mauri et al.   CANCER TREATMENT REVIEWS

Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

(2008) Henrike E. Karim-Kos et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

ADRB3 Adrenergic Receptor Is a Key Regulator of Human Myometrial Apoptosis and Inflammation During Chorioamnionitis1

(2007) Fréderic Lirussi et al.   BIOLOGY OF REPRODUCTION